Edwin L. Parsley
Chief Tech/Sci/R&D Officer bei BELLEROPHON THERAPEUTICS, INC.
Profil
Edwin L.
Parsley is currently the Chief Medical Officer at Bellerophon Therapeutics, Inc. He previously worked as the Director of Global Medical Affairs at Encysive Pharmaceuticals, Inc. and Seqirus GmbH, as well as a Principal at Pfizer Inc. He also served as the Chief Medical Officer and Senior Vice President at Mast Therapeutics, Inc., Liquidia Technologies, Inc., Aires Pharmaceuticals, Inc., and Respira Therapeutics, Inc. Additionally, he was an Assistant Professor at The University of Texas at Austin.
Parsley holds a doctorate from Oklahoma State University and an undergraduate degree from Southwestern Oklahoma State University.
Aktive Positionen von Edwin L. Parsley
Unternehmen | Position | Beginn |
---|---|---|
BELLEROPHON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Ehemalige bekannte Positionen von Edwin L. Parsley
Unternehmen | Position | Ende |
---|---|---|
SAVARA INC. | Chief Tech/Sci/R&D Officer | 27.04.2017 |
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Chief Tech/Sci/R&D Officer | - |
Respira Therapeutics, Inc.
Respira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Respira Therapeutics, Inc. engages in provision of pulmonary delivery of therapeutics for respiratory diseases. Its technology Dry Powder Inhaler (DPI), deliver dry powder drug products to the lung more effectively than other DPI technologies. The company was founded in 2010 and is headquartered in Albuquerque, NM. | Chief Tech/Sci/R&D Officer | - |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
The University of Texas at Austin | Corporate Officer/Principal | - |
Ausbildung von Edwin L. Parsley
Oklahoma State University | Doctorate Degree |
Southwestern Oklahoma State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
PFIZER, INC. | Health Technology |
BELLEROPHON THERAPEUTICS, INC. | Health Technology |
SAVARA INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Health Technology |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
Aires Pharmaceuticals, Inc.
Aires Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Aires Pharmaceuticals, Inc. develops drugs to treat pulmonary disorders. It offers Aironite, an inhaled drug that is used to treat adult and pediatric pulmonary hypertension, cystic fibrosis, pneumonia and other respiratory infections. The company was founded by Wendy S. Johnson in 2006 and is headquartered in San Diego, CA. | Health Services |
Seqirus GmbH
Seqirus GmbH BiotechnologyHealth Technology Part of CSL Ltd., Seqirus GmbH is a German company that develops and produces flu vaccines. The private company is based in Marburg, Germany. The CEOs are Sanat Jeetun, Frank Eberlein. The company was founded in 2002. | Health Technology |
Respira Therapeutics, Inc.
Respira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Respira Therapeutics, Inc. engages in provision of pulmonary delivery of therapeutics for respiratory diseases. Its technology Dry Powder Inhaler (DPI), deliver dry powder drug products to the lung more effectively than other DPI technologies. The company was founded in 2010 and is headquartered in Albuquerque, NM. | Health Technology |